Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by retiredcopon Aug 02, 2018 7:08pm
123 Views
Post# 28407742

RE:RE:RE:Whats going on with the sp?

RE:RE:RE:Whats going on with the sp?You never know what is going to published that could get peoples attention..


Creative Biolabs provides a comprehensive antibody analysis services to make the best understanding for interested antibody property. We offer tailored solutions for antibody analysis to support drug discovery, manufacturing process and any other particular requirements.

Antibody products, monoclonal antibody (mAb) especially, have played a major role of the growing biologics drug market. For the diagnosis and treatment of various disease types, the development of monoclonal antibody therapeutics is almost the largest and most effective choice for oncological, immunological and anti-infective therapeutic areas. One reason of this interest is due to the exquisite specificity of mAbs. In general, a particular antigen can be specifically bound by a monoclonal antibody which has structurally identical antigen-binding regions recognize the same site of the antigen. This specificity can lead to highly selective interactions with interested targets involved in the pathology of disease, such as receptors, tissues and organs, and further minimizing the potential side effects.

Bullboard Posts